EGFR+ Lung Cancer

During a presentation at the <em>16th Annual </em>Winter Lung Cancer Conference,&nbsp;Julie R. Brahmer, MD, MSc shed light on some of the immunotherapy treatment options that could be entering the lung cancer pipeline over the next 5 years.

Edward B. Garon, MD,&nbsp;discusses the newer role of immunotherapy in the treatment of patients with unresectable stage III NSCLC with the approval of durvalumab in this setting for patients whose disease has not progressed following concurrent chemoradiation.

Christina S. Baik, MD, MPH,&nbsp;discusses several existing and emerging treatment options for <em>ROS1</em>, <em>BRAF</em>, and <em>NTRK </em>genetic aberrations.

During a presentation at the 16th Annual Winter Lung Conference, Gregory J. Riely, MD, PhD, discusses how oncologists can differentiate between the&nbsp;many EGFR TKIs available for patients with&nbsp;<em>EGFR</em>-mutant non&ndash;small cell lung cancer.

General Cancer

Bristol-Myers Squibb has announced its decision to withdraw a&nbsp;supplemental biologics license application currently with&nbsp;the FDA seeking frontline approval for the combination of nivolumab and ipilimumab for patients with advanced non&ndash;small cell lung cancer with tumor mutational burden &ge;10 mutations per megabase.

Heather A. Wakelee, MD, discusses the use of osimertinib as a frontline treatment option for patients with <em>EGFR</em>-positive lung cancer.

Both overall survival and progression-free survival were improved in patients with <em>EGFR</em>-mutant nonsquamous cell lung cancer who were treated with the combination of atezolizumab, bevacizumab, and chemotherapy compared with bevacizumab plus chemotherapy, according to an exploratory analysis of the IMpower150 study.

Patients who continued receiving osimertinib after their non&ndash;small cell lung cancer had progressed demonstrated a prolonged benefit beyond the initial progression event, according to a retrospective analysis of 118 patients from The University of Texas MD Anderson Cancer Center and the Moffitt Cancer Center and Research Institute.

Michael Gieske, MD, discusses how his community center was able to implement a lung cancer screening program.

A retrospective analysis of survival data from patients with metastatic non&ndash;small cell lung cancer showed that patients who received treatment at academic centers had better survival rates than those treated at community-based centers, and this disparity was more pronounced when patients were stratified by histology.

A supplemental biologics license application submitted to the FDA for&nbsp;atezolizumab, carboplatin, and nab-paclitaxel has been accepted. The application, based on findings from the&nbsp;phase III IMpower130 trial, is seeking the agent&#39;s approval for&nbsp;patients with metastatic nonsquamous non&ndash;small cell lung cancer.

D. Ross Camidge, MD, PhD,&nbsp;discusses the crowded landscape of oncogene-driven non&ndash;small cell lung cancer.

Increasing clinical relevance of less common gene signatures and alterations is leading to a benefit from broad-panel next-generation sequencing testing for patients with metastatic non&ndash;small cell lung cancer, according to an expert at Memorial Sloan Kettering Cancer Center.

The use of big data is revolutionizing many industries, allowing greater insights by drilling into evidence with more detail.

Due to the significant decline in smoking and an increase in advances for early cancer detection and screening, the cancer death rate has declined 27% in the United States from 1991 to 2016, according to the American Cancer Society&rsquo;s annual report on cancer rates.

A look back at all the&nbsp;FDA news&nbsp;that happened in the month of&nbsp;December 2018, including several new approvals, an accelerated approval, and a priority review.